Minerva Neurosciences NERV
NASDAQ NERV
$4.43 -0.26 (-5.54%)
At close: Sep 4, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Other Non-Current Liabilities (2013 - 2026)

Minerva Neurosciences' (NERV) quarterly Other Non-Current Liabilities came in at $60.0 million in Q1 2026, little changed YoY from $60.0 million in Q1 2025, and little changed on a QoQ basis from $60.0 million in Q4 2025.

Analysis

Minerva Neurosciences (NERV) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

Minerva Neurosciences (NERV) has 11 years of Other Non-Current Liabilities data on file, last reported at $60.0 million in Q1 2026.

  • Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $60.0 million, changed N/A from the prior year.
  • Other Non-Current Liabilities held at $60.0 million in Q1 2026, from $60.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $86.6 million in Q2 2024 to a low of $60.0 million in Q3 2024.
  • A 5-year average of $70.6 million and a median of $70.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2024 — Other Non-Current Liabilities climbed 11.37% — and 2025, when it tumbled 30.7%.
  • Tracing NERV's Other Non-Current Liabilities over 5 years: stood at $73.7 million in 2022, then rose by 11.23% to $82.0 million in 2023, then fell by 26.84% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $60.0 million (Q1 2026), $60.0 million (Q4 2025), and $60.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Minerva Neurosciences 207.37 Mn 207.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 232.69 Mn
Mar 31, 2026 278.60 Mn
Dec 31, 2025 171.46 Mn
Sep 30, 2025 60.00 Mn
Jun 30, 2025 60.00 Mn
Mar 31, 2025 60.00 Mn
Dec 31, 2024 60.00 Mn
Sep 30, 2024 60.00 Mn
Jun 30, 2024 86.58 Mn
Mar 31, 2024 84.27 Mn
Dec 31, 2023 82.02 Mn
Sep 30, 2023 79.83 Mn
Jun 30, 2023 77.74 Mn
Mar 31, 2023 75.71 Mn
Dec 31, 2022 73.73 Mn
Sep 30, 2022 71.81 Mn
Jun 30, 2022 69.93 Mn
Mar 31, 2022 68.11 Mn
Dec 31, 2021 66.33 Mn
Sep 30, 2021 64.59 Mn